Chronic brain ischemia in youthful age persons with undifferentiated connective tissue dysplasia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Factors unfavorable for the development of chronic cerebral ischemia (CCI), such as arterial hypotension and cardiac arrhythmias due to vegetative dysregulation, blood flow disturbances in brachiocephalic vessels, anemic syndrome are often found in people with undifferentiated connective tissue dysplasia (UCTD). Clinically, the early stages of CCI occur in the form of cognitive and psychovegetative disorders, which are also UCTD characteristics. Such a biomarker as antibodies to the NR-2 peptide (NR2-At) determines the past cerebral ischemia. The aim: to study the correlation of UCTD with cerebral ischemia development in youthful age people. Material and methods. The study involved 80 persons aged 18-22 studying at the ASMU. According to the content of NR2-At, 2 groups were separated: with normal (control group, n=23) and increased (comparison group, n=57) titer of this marker. A general clinical and neuropsychological examination was carried out, markers of anemia, inflammation, neurotrophism, neurodegeneration were studied, duplex scanning of brachiocephalic vessels, electroencephalography were performed. Results. The marker of cerebral ischemia was elevated in 71% of students. Autonomic dysfunction, asthenia, anxiety, depression, headache index were higher in the comparison group. A significant increase in NR2-At was found in the group with severe UCTD. Presence of UCTD, headaches, a decrease in red blood indexes, and female sex were the predictors associated with an increase in the chances of cerebral ischemia developing. Conclusion. A correlation between the development of cerebral ischemia and severe UCTD in youthful age people has been established, so the dysplastic process correction can become an important part in prevention and treatment of CCI and non-psychotic mental disorders. Obtained results allow us to consider pronounced UCTD as an independent risk factor for the development of CCI.

Full Text

Restricted Access

About the authors

Irina V. Maltseva

Altai State Medical University of the Ministry of Healthcare of Russia

assistant at the Department of propaedeutics of internal diseases named after prof. Z.S. Barkagan

Irina I. Sheremetyeva

Altai State Medical University of the Ministry of Healthcare of Russia

Dr. med. habil., professor, Rector, head of the Department of psychiatry, medical psychology and narcology with the course of FVE

Elena F. Kotovschikova

Altai State Medical University of the Ministry of Healthcare of Russia

Dr. med. habil., professor, head of the Department of propaedeutics of internal diseases named after prof. Z.S. Barkagan

Alexander E. Stroganov

Altai State Medical University of the Ministry of Healthcare of Russia

Dr. med. habil., associate professor, professor of the Department of psychiatry, medical psychology and narcology with course of FVE

Vitaly L. Lukinov

Institute of Computational Mathematics and Mathematical Geophysics of the Siberian branch of the Russian Academy of Sciences

candidate of physical and mathematical sciences, senior researcher, head of the Laboratory for numerical analysis of stochastic differential equations

References

  1. Живолупов С.А. Самарцев И.Н. Современный клинический анализ цереброваскулярных заболеваний: узловые вопросы дифференциальной диагностики и патогенетического лечения. Фарматека. 2012; 7: 87-94. [Zhivolupov S.A., Samartsev I.N. Modern clinical analysis of cerebrovascular diseases: key issues of differential diagnosis and pathogenetic treatment. Farmateka. 2012; 7: 87-94 (In Russ.)]. EDN: PBPCAL.
  2. Табеева Г. Р., Калимеева Е.Ю., Коберская Н.Н., Гереева С.И. Возможности терапии ранних проявлений хронической ишемии головного мозга: результаты программы «ПРОФИЛЬ». Неврология, нейропсихиатрия, психосоматика. 2017; 9(3): 36-41. [Tabeeva G.R., Kalimeeva E.Yu., Koberskaya N.N., Gereeva S.I. Possibilities of therapy for early manifestations of chronic cerebral ischemia: results of the PROFILE program. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017; 9(3): 36-41 (In Russ.)]. http://dx.doi.org/10.14412/2074-2711-2017-3-36-41. EDN: ZXXRWJ.
  3. Петрова Е.А., Кольцова Е.А. Антиагрегантная терапия ишемической болезни головного мозга. Нервные болезни. 2017; 3: 50-55. [Petrova E.A., Koltsova E.A. Antiplantet therapy of ishemic brain disease. Nervnye bolezni = Nervous Diseases. 2017; 3: 50-55 (In Russ.)]. EDN: ZSHHZH.
  4. Чуканова Е.И., Чуканова А.С. Современные методы лечения хронической цереброваскулярной недостаточности: роль нейротрофинов. Эффективная фармакотерапия. 2018: 20: 70-77. EDN: YAUQHJ.
  5. Хроническая недостаточность мозгового кровообращения. Неврология: национальное руководство. Под ред. Е.И. Гусева, А.Н. Коновалова, В.И. Скворцовой. М.: ГЭОТАР-Медиа. 2018; 338-349. [Chronic insufficiency of cerebral circulation. Neurology: a national guide. Ed. by Guseva E.I., Konovalov A.N., Skvortsova V.I. Moscow: GEOTAR-Media. 2018: pp. 338-349 (In Russ.)]. ISBN: 978 5-9704-6159-4.
  6. Шишкова В.Н., Адашева Т.В. Хроническая ишемия головного мозга и головная боль у пациентов в практике терапевта. Неврология, нейропсихиатрия, психосоматика. 2021; 13(1): 131-137. http://dx.doi.org/10.14412/2074-2711-2021-1-131-137. EDN: AWBMZP.
  7. Фатеева В.В., Шумахер Г.И., Воробьева Е.Н. с соавт. Эффективность и безопасность применения препарата Диваза в терапии пациентов с хронической ишемией головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017; 117(2): 32-37. [Fateeva V.V., Shumacher G.I., Vorobyova E.N. et al. The efficacy and safety of drug therapy Divaza in patients with chronic cerebral ischemia. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2017; 117(2): 32-37 (In Russ.)]. http://dx.doi.org/10.17116/jnevro20171172132-37. EDN: YHEQET.
  8. Шишкова В.Н. Новые возможности оценки эффективности вторичной профилактики ишемического инсульта в терапевтической практике. Consilium Medicum. 2019: 21(2): 43-47. http://dx.doi.org/10.26442/20751753.2019.2.190216. EDN: IUAGYD.
  9. Камчатнов П.Р., Евзельман М.А., Морозова Ю.А. Хронические расстройства мозгового кровообращения: возможности повышения эффективности терапии. Неврология, нейропсихиатрия, психосоматика. 2017; 9(3): 105-110. [Kamchatnov P.R., Evzelman M.A., Morozova Yu.A. Chronic cerebral circulatory disorders: possibilities of enhancing the efficiency of therapy. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017; 9(3): 105-110 (In Russ.)]. http://dx.doi.org/10.14412/2074-2711-2017-3-105-110. EDN: ZXXSAP.
  10. Коберская Н.Н., Табеева Г.Р., Калимеева Е.Ю., Гереева С.И. Начальные формы цереброваскулярной недостаточности: подходы к терапии (по результатам клинико-эпидемиологической программы «Профиль»). Медицинский Совет. 2018; 1: 13-19. [Koberskaya N.N., Tabeeva G.R., Kalimeeva E.Yu., Gereeva S.I. Initial forms of cerebrovascular insufficiency: different approaches to therapy (on the results of the clinical and epidemiological program «Profile»). Meditsinskiy sovet = Medical Council. 2018; 1: 13-19 (In Russ.)]. http://dx.doi.org/10.21518/2079-701X-2018-1-13-19. EDN: YNMMMW.
  11. Екушева Е.В. Цереброваскулярные заболевания и цефалгии. РМЖ. 2019; 27(9): 11-16. [Yekusheva Ye.V. Cerebrovascular diseases and cephalalgia. Russkiy Meditsinskiy Zhurnal = Russian Medical Journal. 2019; 27(9): 11-16 (In Russ.)]. EDN: ASXFRY.
  12. Емелин А.Ю. Когнитивные нарушения при цереброваскулярной болезни - что между нормой и деменцией? Неврология, нейропсихиатрия, психосоматика. 2015; 7(1): 94-98. [Emelin A.Yu. Cognitive impairments in cerebrovascular disease: What is between health andementia? Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2015; 7(1): 94-98 (In Russ.)]. http://dx.doi.org/10.14412/2074-2711-2015-1-94-98. EDN: TMHNVR.
  13. Хунтеев Г.А., Заволоков И.Г., Черкас Ю.В., Дамбинова С.А. Практическое значение определения уровня аутоантител к NMDA-типу глутаматных рецепторов в диагностике хронических расстройств мозгового кровообращения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2001; 101(11): 44-47. [Khunteev G.A., Zavolokov I.G., Cherkas Yu.V., Dambinova S.A. Significance of the level of autoantibodies to NMDA type glutamate receptors in diagnosis of chronic cerebral circulation disorders. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2001; 101(11): 44-47 (In Russ.)]. EDN: ZUNDIZ.
  14. Топузова М.П., Алексеева Т.М., Панина Е.Б. с соавт. NR2-антитела как диагностический и прогностический биомаркер при инсульте. Артериальная гипертензия. 2020; 26(1): 27-36. [Topuzova M.P., Alekseeva T.M., Panina E.B. et al. NR2 antibodies as diagnostic and prognostic stroke biomarker. Arterial'naya gipertenziya = Arterial Hypertension. 2020; 26(1): 27-36 (In Russ.)]. https://dx.doi.org/10.18705/1607-419X-2020-26-1-27-36. EDN: BQCNRB.
  15. Алексеева Т.М., Топузова М.П., Чайковская А.Д. с соавт. Новые диагностические и прогностические биомаркеры ишемических поражений мозга. Трансляционная медицина. 2020; 7(5): 29-42. [Alekseeva T.M., Topuzova M.P., Chaykovskaya A.D. et al. New diagnostic and prognostic biomarkers of the ischemic brain damage. Translyatsionnaya meditsina = Translational Medicine. 2020; 7(5): 29-42 (In Russ.)]. https://dx.doi.org/10.18705/2311-4495-2020-7-5-29-42. EDN: ZECLRB.
  16. Нечайкина С.А., Мальмберг С.А., Петрухин А.С. Неврологические нарушения при дисплазии соединительной ткани у детей и их коррекция. Русский журнал детской неврологии. 2010; 5(3): 11-19. [Nechaykina S.A., Malmberg S.A., Petrukhin A.S. Neurologic disorders associated with dysplasia of connective tissue in children and their correction. Russkii zhurnal detskoi nevrologii = Russian Journal of Child Neurology. 2010; 5(3): 11-19 (In Russ.)]. EDN: OJOTOT.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies